Cargando…
Complement activation during cardiopulmonary bypass and association with clinical outcomes
In this prospective, single‐centre observational study of 30 patients undergoing cardiopulmonary bypass (CPB), the effect of unfractionated heparin (UFH), CPB surgery and protamine sulphate on complement and on post‐operative blood loss were assessed. Although C3 and C4 levels decreased significantl...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175769/ https://www.ncbi.nlm.nih.gov/pubmed/35846208 http://dx.doi.org/10.1002/jha2.371 |
_version_ | 1784722520484610048 |
---|---|
author | Kefalogianni, Rengina Kamani, Farah Gaspar, Mihaela Aw, TC Donovan, Jackie Laffan, Mike Pickering, Matthew C. Arachchillage, Deepa J. |
author_facet | Kefalogianni, Rengina Kamani, Farah Gaspar, Mihaela Aw, TC Donovan, Jackie Laffan, Mike Pickering, Matthew C. Arachchillage, Deepa J. |
author_sort | Kefalogianni, Rengina |
collection | PubMed |
description | In this prospective, single‐centre observational study of 30 patients undergoing cardiopulmonary bypass (CPB), the effect of unfractionated heparin (UFH), CPB surgery and protamine sulphate on complement and on post‐operative blood loss were assessed. Although C3 and C4 levels decreased significantly immediately following the administration of UFH, C3a, C5a, Bb fragment and SC5b‐9 remained unchanged. During CPB, C3 and C4 continued to fall whilst both alternative and classical pathways activation markers, Bb, C3a, C5a and SC5b‐9 increased significantly. Protamine sulphate had no effect on classical pathway components or activation markers but decreased alternative pathway activation marker Bb. Over the 12–24 h post‐surgery, both classical and alternative pathway activation markers returned to baseline, whilst C3 and C4 levels increased significantly but not to baseline values. Total drain volume 24 h after the surgery showed a moderate inverse correlation with post‐protamine C3 (r = −0.46, p = 0.01) and C4 (r = −0.57, p = 0.0009) levels, whilst a moderate positive correlation was observed with post‐protamine C3a (r = 0.46, p = 0.009), C5a (r = 0.37, p = 0.04) and SC5b‐9 (r = 0.56, p = 0.001) levels but not with Bb fragment (r = 0.25, p = 0.17). Thus, inhibition of complement activation may be a therapeutic intervention to reduce post‐operative blood in patients undergoing CPB. |
format | Online Article Text |
id | pubmed-9175769 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91757692022-07-14 Complement activation during cardiopulmonary bypass and association with clinical outcomes Kefalogianni, Rengina Kamani, Farah Gaspar, Mihaela Aw, TC Donovan, Jackie Laffan, Mike Pickering, Matthew C. Arachchillage, Deepa J. EJHaem Sickle Cell, Thrombosis, and Benign Haematology In this prospective, single‐centre observational study of 30 patients undergoing cardiopulmonary bypass (CPB), the effect of unfractionated heparin (UFH), CPB surgery and protamine sulphate on complement and on post‐operative blood loss were assessed. Although C3 and C4 levels decreased significantly immediately following the administration of UFH, C3a, C5a, Bb fragment and SC5b‐9 remained unchanged. During CPB, C3 and C4 continued to fall whilst both alternative and classical pathways activation markers, Bb, C3a, C5a and SC5b‐9 increased significantly. Protamine sulphate had no effect on classical pathway components or activation markers but decreased alternative pathway activation marker Bb. Over the 12–24 h post‐surgery, both classical and alternative pathway activation markers returned to baseline, whilst C3 and C4 levels increased significantly but not to baseline values. Total drain volume 24 h after the surgery showed a moderate inverse correlation with post‐protamine C3 (r = −0.46, p = 0.01) and C4 (r = −0.57, p = 0.0009) levels, whilst a moderate positive correlation was observed with post‐protamine C3a (r = 0.46, p = 0.009), C5a (r = 0.37, p = 0.04) and SC5b‐9 (r = 0.56, p = 0.001) levels but not with Bb fragment (r = 0.25, p = 0.17). Thus, inhibition of complement activation may be a therapeutic intervention to reduce post‐operative blood in patients undergoing CPB. John Wiley and Sons Inc. 2022-01-13 /pmc/articles/PMC9175769/ /pubmed/35846208 http://dx.doi.org/10.1002/jha2.371 Text en © 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Sickle Cell, Thrombosis, and Benign Haematology Kefalogianni, Rengina Kamani, Farah Gaspar, Mihaela Aw, TC Donovan, Jackie Laffan, Mike Pickering, Matthew C. Arachchillage, Deepa J. Complement activation during cardiopulmonary bypass and association with clinical outcomes |
title | Complement activation during cardiopulmonary bypass and association with clinical outcomes |
title_full | Complement activation during cardiopulmonary bypass and association with clinical outcomes |
title_fullStr | Complement activation during cardiopulmonary bypass and association with clinical outcomes |
title_full_unstemmed | Complement activation during cardiopulmonary bypass and association with clinical outcomes |
title_short | Complement activation during cardiopulmonary bypass and association with clinical outcomes |
title_sort | complement activation during cardiopulmonary bypass and association with clinical outcomes |
topic | Sickle Cell, Thrombosis, and Benign Haematology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175769/ https://www.ncbi.nlm.nih.gov/pubmed/35846208 http://dx.doi.org/10.1002/jha2.371 |
work_keys_str_mv | AT kefalogiannirengina complementactivationduringcardiopulmonarybypassandassociationwithclinicaloutcomes AT kamanifarah complementactivationduringcardiopulmonarybypassandassociationwithclinicaloutcomes AT gasparmihaela complementactivationduringcardiopulmonarybypassandassociationwithclinicaloutcomes AT awtc complementactivationduringcardiopulmonarybypassandassociationwithclinicaloutcomes AT donovanjackie complementactivationduringcardiopulmonarybypassandassociationwithclinicaloutcomes AT laffanmike complementactivationduringcardiopulmonarybypassandassociationwithclinicaloutcomes AT pickeringmatthewc complementactivationduringcardiopulmonarybypassandassociationwithclinicaloutcomes AT arachchillagedeepaj complementactivationduringcardiopulmonarybypassandassociationwithclinicaloutcomes |